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As pre-transplant pulmonary function tests were not systematically performed before 2006 in our institution, the HCT-CI was assessable only for patients who underwent PB-HSCT between January 2006 and December 2010.
Transplant modalities and outcomes: definitions
Myeloablative conditioning (MAC) regimens included either high dose busulfan (dose > 8 mg/kg orally or intravenous equivalent) or high dose total body irradiation (≥8Gy fractioned dose), both associated with cyclophosphamide. Regimens not meeting these criteria were classified as reduced intensity conditioning (RIC). A count of 4.5x10 6 CD34+ cells/kg recipient's weight was defined as the cut-off for low and high CD34+ cell dose, based on institutional guidelines and previous studies 40 . OS was defined as the time from HSCT to death from any cause. PFS was considered as the time from HSCT to disease relapse or progression or death from any cause, whichever occurred first. Relapse was defined as recurrence of the original malignancy. NRM was considered as death from any cause in patients who did not relapse. Chronic GVHD was diagnosed according to the 2005 NIH Consensus Criteria.
Statistical methods: variables
Tested variables in univariate analysis included (only pre-transplant parameters): donor type (MRD vs. MUD), patient age at transplant, DRI, donor age, donor/recipient gender match (female donor/ male recipient vs. other combinations), donor/recipient CMV sero-status match, donor/recipient ABO blood groups match, graft CD34+ cell dose, graft CD3+ cell dose, conditioning regimen intensity (MAC vs. RIC) and use of antithymocyte globulin (ATG) as part of conditioning regimen or for GVHD prophylaxis. Because a donor age ≥ 60 years appeared to be associated with survival in univariate analysis and because 60 years was the usual upper age limit for MUD, we further defined 3 groups of donors according to type and age: MUD, MRD younger than 60 years (MRD<60y) and MRD aged 60 years or older (MRD ≥60y). We used the new defined variable (donor type/age group) in the multivariate setting. Concerning OS and PFS, because evidence of non-proportional hazards according to time from HSCT for donor type/age groups (MRD ≥60y : P=0.003 and P=0.014 for OS and PFS, respectively), we performed a time-dependent effects analysis for this variable by assessing hazards during four successive quartiles of time, each corresponding to a period during which 25% of deaths had occurred within the entire cohort (0 to 6, 6 to 9, 9 to 18 and ≥ 18 months after PB-HSCT). Table S1 . Univariate analysis of prognostic value of pre-transplant factors on outcomes after PB-HSCT. Hazard ratio (HR) and P-value are shown. 
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